Former GSK Exec Indicted Over Wellbutrin Off-Label Promotion Claims

November 10, 2010
A former GlaxoSmithKline (GSK) vice president and associate general counsel is accused of withholding documents from the FDA that apparently show off-label promotion of its antidepressant Wellbutrin. In an indictment in a federal court in Maryland, the Justice Department charged Lauren Stevens with four counts of making false statements to the FDA, one count of obstructing an official proceeding and one count of concealing and falsifying documents to influence a federal agency.
Drug Industry Daily